Potential

Allstate, Sompo & Lloyd's Answer Your GenAI Questions to Build Your AI Foundation in Claims

Retrieved on: 
Thursday, April 4, 2024

Chicago, Illinois--(Newsfile Corp. - April 4, 2024) - AI was recently the latest 'shiny new toy' that enabled claims departments to delve into automation.

Key Points: 
  • Chicago, Illinois--(Newsfile Corp. - April 4, 2024) - AI was recently the latest 'shiny new toy' that enabled claims departments to delve into automation.
  • Then, before we have even got up to speed, GenAI came on the scene to revolutionize claims from streamlining claims processing, to data insight, to fraud detection.
  • However, we have a lot of questions to answer before we can build a foundation for AI usage and really see these benefits.
  • Tune into our next webinar to get your answers - From AI to GenAI: Unlock the Potential for Claims (April 16th, 11am EST or On Demand)
    Discover where AI and GenAI can most benefit you, and start seeing the impact now:
    Develop your AI roadmap and decide on your comfort zone: Have impact with AI now, keeping human in the loop, and be ready to hit the ground running when AI matures enough to be scalable and really change the claims game
    Prepare with your data experts: It's not just about strategizing and deciding where to deploy AI, work with your data team to create an accessible data warehouse full of rich data that will train and fuel your AI algorithms
    Let's get started: Implement GenAI where these is low risk but high reward - free up adjusters with document summaries, automate claims allocation, identify risk trends and make huge efficiency gains
    Our panellists have real life experience and learnings from pushing forward with AI innovations:
    Don Jones, SVP Claims Design & Delivery, Allstate
    Understand AI, decide where you need it, and get started now so you're not behind by the next innovation.

Pineapple Energy Encourages Shareholders to Vote FOR the Reverse Stock Split and Increase in Authorized Shares

Retrieved on: 
Monday, April 8, 2024

The Board of Directors emphasizes the importance of this shareholders’ vote, specifically urging for a positive vote FOR the reverse stock split and FOR the increase in authorized shares.

Key Points: 
  • The Board of Directors emphasizes the importance of this shareholders’ vote, specifically urging for a positive vote FOR the reverse stock split and FOR the increase in authorized shares.
  • The Board believes that the reverse stock split and increase in authorized shares is instrumental for several reasons, including:
    Maintenance with Nasdaq Listing Status: If the Reverse Stock Split Proposal is not approved by the Company’s shareholders, the Company’s common stock may be delisted from Nasdaq.
  • Shareholders must approve the increase in authorized shares in order for the Company to have enough authorized shares to meet these obligations.
  • It is essential to understand that a reverse stock split consolidates existing shares, preserving the Company’s overall value and each shareholder’s respective ownership percentage.

Bio-Path Holdings Provides 2024 Clinical and Operational Update

Retrieved on: 
Tuesday, April 2, 2024

HOUSTON, April 02, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today provides a clinical development and operational update for 2024.

Key Points: 
  • HOUSTON, April 02, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today provides a clinical development and operational update for 2024.
  • Prexigebersen Phase 2 Clinical Trial – Bio-Path’s Phase 2 clinical trial is treating Acute Myeloid Leukemia (AML) patients.
  • Phase 1/1b Clinical Trial in BP1002 in Relapsed/Refractory AML – A Phase 1/1b clinical trial for BP1002 to treat relapsed/refractory AML patients, including venetoclax-resistant patients, is ongoing.
  • In January 2024, Bio-Path announced successful completion of the first dose cohort in the Phase 1 clinical trial.

Vincerx Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Update

Retrieved on: 
Friday, March 29, 2024

PALO ALTO, Calif., March 29, 2024 (GLOBE NEWSWIRE) --  Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided a corporate update.

Key Points: 
  • Vincerx presented preclinical data at the 2023 AACR Annual Meeting demonstrating significant activity in patient-derived xenograft (PDX) lymphoma mouse models.
  • Vincerx shared preclinical data at the 2023 ASH Annual Meeting showing superior activity and safety compared with commercially available B-cell targeted ADCs.
  • For the fourth quarter and full year 2023, Vincerx reported a net loss of $4.9 million, or $0.23 per share, and a net loss of $40.2 million, or $1.89 per share, respectively.
  • For the fourth quarter and full year 2022, Vincerx reported a net loss of $13.8 million, or $0.65 per share, and a net loss of $63.0 million, or $3.00 per share, respectively.

TFF Pharmaceuticals Announces Updated Data from the Tacrolimus Inhalation Powder (TFF TAC) and Voriconazole Inhalation Powder (TFF VORI) Clinical Programs

Retrieved on: 
Wednesday, March 27, 2024

FORT WORTH, Texas , March 27, 2024 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) (“the Company”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced updated data from the Tacrolimus Inhalation Powder (TFF TAC) and Voriconazole Inhalation Powder (TFF VORI) clinical programs.

Key Points: 
  • “Based on the totality of these clinical data, we believe TFF TAC and TFF VORI have the potential to establish a new and significantly improved form of delivery for these two life-saving medicines.
  • The updated safety and efficacy data are based on the cutoff date of March 8, 2024.
  • The ongoing Phase 2 trial of TFF TAC is an open-label study in lung transplant patients who require reduced tacrolimus blood levels due to kidney toxicity.
  • The Company will host a conference call today at 4:30 pm Eastern Time, to discuss updated data for the Tacrolimus Inhalation Powder (TFF TAC) and Voriconazole Inhalation Powder (TFF VORI) clinical programs.

iVaCay Launches ICO Campaign to Revolutionize Vacation Ownership

Retrieved on: 
Thursday, March 21, 2024

Unlocking the Potential of Experiential Travel: VacayCoin ICO Launch

Key Points: 
  • Unlocking the Potential of Experiential Travel: VacayCoin ICO Launch
    iVaCay's ICO campaign offers early access to VacayCoin, a groundbreaking platform that tokenizes vacation assets, providing fractional ownership and flexible trading opportunities.
  • Embracing Innovation in Vacation Ownership: iVaCay's Unique Utility Services
    iVaCay's utility services redefine vacation ownership, offering unparalleled flexibility, security, and transparency.
  • Through tokenization, iVaCay enables fractional ownership of vacation properties, facilitating liquidity and trading on blockchain-based platforms.
  • iVaCay's ongoing ICO campaign offers early investment in VacayCoin, a groundbreaking platform that merges blockchain technology with experiential travel.

TFF Pharmaceuticals Announces Update on Clinical Programs

Retrieved on: 
Wednesday, March 20, 2024

FORT WORTH, Texas, March 20, 2024 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) (“the Company”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, is announcing data updates and strategic prioritization of its clinical programs. Based on positive data from the ongoing Phase 2 study of TFF TAC, the potential to address a significant unmet need in lung transplant medicine, and substantial market opportunity, the Company has made the decision to prioritize the TFF TAC program and focus resources on the acceleration of its clinical pathway towards registration.

Key Points: 
  • “However, after a rigorous assessment of our pipeline, including the significant capital and resources required to progress both clinical development programs, we will focus our clinical development efforts and financial resources on TFF TAC.
  • In summary, for TFF TAC, eight out of eight patients have successfully transitioned from oral Tacrolimus to TFF TAC in the Phase 2 study.
  • TFF TAC continues to demonstrate favorable safety results with no mortality or discontinuations due to adverse events.
  • The Company will host a conference call on Wednesday, March 27, 2024, at 4:30 PM Eastern Time, to discuss updated clinical data for the TFF TAC and TFF VORI.

Nubis to Showcase Award-Winning 1.6Tbps Optical Module Optimized for ML/AI Clusters at OFC 2024

Retrieved on: 
Thursday, March 21, 2024

The company will be showcasing its uniquely scalable XT1600 module made possible by a novel 2D optical-fiber array and highly integrated high-speed silicon photonics.

Key Points: 
  • The company will be showcasing its uniquely scalable XT1600 module made possible by a novel 2D optical-fiber array and highly integrated high-speed silicon photonics.
  • Live demonstrations of the XT1600 carrying Ethernet and PCIe Gen 6 signals will be shown in Nubis’ meeting room MR5510 during Exhibit Hall hours from March 26 – 28.
  • The Nubis optical engine can also be seen operating PCIe Gen 6 traffic with Alphawave Semi’s PipeCORE PHY with PiCORE Controller in both the Nubis room and Alphawave Semi’s room MR5617.
  • Award: Nubis Communications will receive its award from Lightwave Innovation Review in a ceremony on March 25 at 17:00.

Sol-Millennium Responds to FDA’s Warning Letter and Safety Communication

Retrieved on: 
Thursday, March 21, 2024

Sol-Millennium, manufacturer of medical devices, including syringes for medicine delivery and testing, issued a statement regarding March 19th update to the FDA’s Safety Communication (“Evaluating Plastic Syringes Made in China for Potential Device Failures”) and a Warning Letter to Sol-Millennium.

Key Points: 
  • Sol-Millennium, manufacturer of medical devices, including syringes for medicine delivery and testing, issued a statement regarding March 19th update to the FDA’s Safety Communication (“Evaluating Plastic Syringes Made in China for Potential Device Failures”) and a Warning Letter to Sol-Millennium.
  • Since November 2023, Sol-Millennium has been providing reports of actions it has taken to address any findings identified in the Warning Letter.
  • The principal focus of the Warning Letter is on our 510(k) and whether our “combination” products (needle + syringe attached) constitute a significant change or modification in design that could significantly alter the safety and effectiveness of the devices.
  • These are the two manufacturers cited in the FDA’s Safety Communication Letter that the FDA recommends to “Immediately transition away from using plastic syringes manufactured” by these manufactures… “[because of] potential quality and performance issues”.

Sasha ApS is Revealing the Potential of Danish World Patented Invention That Can Stop Online Image Abuse for Good

Retrieved on: 
Friday, March 15, 2024

Sasha ApS, a Danish startup specializing in image protection technology, announces its event "Revealing the Potential" to mark the International Day of Conscience.

Key Points: 
  • Sasha ApS, a Danish startup specializing in image protection technology, announces its event "Revealing the Potential" to mark the International Day of Conscience.
  • View the full release here: https://www.businesswire.com/news/home/20240315859380/en/
    Thomas Eriksson, Founder and CEO of Sasha, and Chief Communications Officer, Lotte Thor Høgsberg getting ready for the big reveal.
  • The event will conclude with a housewarming session and Sasha will provide snacks, food, and drinks throughout the event.
  • Our system can even recognize the image again without needing the original photo, ensuring complete privacy for the user,” says Maziar Zamani, CTO of the Danish startup.